Voir la source de Best 5 Fearsome ABT-263 Evidence

Median warm and cold ischemic time was 16?min (11�C29) and seven?h (5.5�C8.4). Livers were transplanted as a whole organ (4), reduced graft (8), formal split (1) or auxiliary transplant (1). Compared to DBD recipients AST was significantly higher on the first three post-operative days and there was no difference in the INR, bilirubin or GGT out to 12?months. There were no biliary or vascular complications and patient and graft survival is 100% at a median follow-up of 41.8?months (1.7�C74?months). LT with DCD grafts in pediatric recipients can be performed with low morbidity and excellent short-to-medium term patient and graft outcome. ""Wedekin M, Ehrich JHH, Pape L. Effective treatment of anemia in pediatric kidney [http://www.selleckchem.com/products/ABT-263.html selleck] transplant recipients with methoxy polyethylene glycol-epoetin beta. Pediatr Transplantation 2011: 15: 329�C333. ? 2011 John Wiley & Sons A/S. Abstract:? MPG-EPO is a continuous erythropoietin receptor activator with a longer half-life than darbepoetin, hence requires less frequent injections. It has been successfully used [http://en.wikipedia.org/wiki/ROR1 ROR1] in adults, but currently, there are no published data available for its use in children. This pilot study was performed to verify the effect of MPG-EPO on Hb levels in children. Twelve patients (age 6.4�C17.2?yr) were treated with MPG-EPO as an individual ��Heilversuch�� according to German law after RTx. Five patients were switched from DA, and seven were na?ve to erythropoietin. Over a period of six?months, Hb levels were measured monthly. A median MPG-EPO dose of 2.5?��g/kg was administered intravenously in a single dose every four?wk. The median Hb value increased in na?ve patients from 9.9 to 11.2?g/dL (median, p?=?0.004) and from 10.3 to 11.6?g/dL (median, p?=?0.39) in patients switched from DA to MPG-EPO. No adverse events secondary to MPG-EPO therapy were detected. Our results indicate that a once-monthly injection of MPG-EPO is an effective treatment of anemia in children after renal transplantation. Larger randomized trials will have [http://www.selleckchem.com/products/MK-2206.html MK 2206] to confirm our findings. ""Racial disparities in transplantation rates and outcomes have not been investigated in detail for NZ, a country with unique demographics. We studied a retrospective cohort of 215 patients